about
A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cellsIdentification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.IGFBP-3 and apoptosis--a license to kill?Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast.Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.Evaluation of the impact of National Breast Cancer Foundation-funded research.Synthesis and in vitro evaluation of analogues of avocado-produced toxin (+)-(R)-persin in human breast cancer cells.Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation.Butyrate- but not TGFbeta1-induced apoptosis of colorectal adenoma cells is associated with increased expression of the differentiation markers E-cadherin and alkaline phosphatase.Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells.Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling.Identification of downstream targets of estrogen and c-myc in breast cancer cells.Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer
P50
Q28264416-F47B1C1E-9FD6-47AC-A655-AF5AF835AAECQ33361574-D940B962-21D3-4A39-B1C6-346E930FC264Q34271028-03872A9A-27C6-4D1B-B9BC-DBE2585E1131Q34857146-1712F9DE-905B-4300-936B-3B4DC004ED9CQ36236632-C269254C-2550-4338-86E3-34379D7573DFQ37080948-28171A69-4563-4110-B723-8086C801170CQ37385287-DD947ABF-926F-4820-BFF2-FEF2A15E3F3BQ38399650-EFFB2AF0-AB38-4EA2-A8B7-4EAE63CAD053Q39449541-045C7F20-191D-44D7-897E-45F86C9F66A1Q39579728-3EFDE707-4B03-4151-98F9-D4B7A302E424Q39780631-6C6CF185-2FCB-40F6-AB0B-5FCDCEDCEDEDQ40319429-2D9ECC72-A33E-4F92-8BA1-BA28AB60EE45Q40440453-D20CCC5F-9EED-44BB-9871-F67870BEC0EDQ40568878-9F172E84-A73A-4727-B283-7C1EB3B148A7Q53475909-E6D7038A-7F18-4E24-B819-F5763BDE44EBQ84115184-16AE0A32-3A39-4BAF-B07B-D0722C0EC5BE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alison J Butt
@ast
Alison J Butt
@en
Alison J Butt
@es
Alison J Butt
@nl
type
label
Alison J Butt
@ast
Alison J Butt
@en
Alison J Butt
@es
Alison J Butt
@nl
prefLabel
Alison J Butt
@ast
Alison J Butt
@en
Alison J Butt
@es
Alison J Butt
@nl
P106
P31
P496
0000-0002-6216-5105